WO2004096156A3 - Toll-like receptor 9 effector agents and uses thereof - Google Patents

Toll-like receptor 9 effector agents and uses thereof Download PDF

Info

Publication number
WO2004096156A3
WO2004096156A3 PCT/US2004/013816 US2004013816W WO2004096156A3 WO 2004096156 A3 WO2004096156 A3 WO 2004096156A3 US 2004013816 W US2004013816 W US 2004013816W WO 2004096156 A3 WO2004096156 A3 WO 2004096156A3
Authority
WO
WIPO (PCT)
Prior art keywords
toll
receptor
effector agents
binding agents
tlr9
Prior art date
Application number
PCT/US2004/013816
Other languages
French (fr)
Other versions
WO2004096156A2 (en
Inventor
Ashlyn Bassiri
Anuk Das
Susan Dillon
Karen Duffy
Jonathan Seideman
Lars Karlsson
Sun Siquan
Jian Zhu
M Lamine Mbow
Original Assignee
Centocor Inc
Ashlyn Bassiri
Anuk Das
Susan Dillon
Karen Duffy
Jonathan Seideman
Lars Karlsson
Sun Siquan
Jian Zhu
M Lamine Mbow
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centocor Inc, Ashlyn Bassiri, Anuk Das, Susan Dillon, Karen Duffy, Jonathan Seideman, Lars Karlsson, Sun Siquan, Jian Zhu, M Lamine Mbow filed Critical Centocor Inc
Priority to CA002524071A priority Critical patent/CA2524071A1/en
Priority to EP04751272A priority patent/EP1620070A2/en
Publication of WO2004096156A2 publication Critical patent/WO2004096156A2/en
Publication of WO2004096156A3 publication Critical patent/WO2004096156A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Cell surface TLR9 and TLR9 ligand binding agents are disclosed. The binding agents include antibodies and other proteins. The binding agents are useful as therapeutics, diagnostics or research reagents.
PCT/US2004/013816 2003-04-29 2004-04-29 Toll-like receptor 9 effector agents and uses thereof WO2004096156A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CA002524071A CA2524071A1 (en) 2003-04-29 2004-04-29 Toll-like receptor 9 effector agents and uses thereof
EP04751272A EP1620070A2 (en) 2003-04-29 2004-04-29 Toll-like receptor 9 effector agents and uses thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46634103P 2003-04-29 2003-04-29
US60/466,341 2003-04-29

Publications (2)

Publication Number Publication Date
WO2004096156A2 WO2004096156A2 (en) 2004-11-11
WO2004096156A3 true WO2004096156A3 (en) 2009-04-02

Family

ID=33418366

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/013816 WO2004096156A2 (en) 2003-04-29 2004-04-29 Toll-like receptor 9 effector agents and uses thereof

Country Status (3)

Country Link
EP (1) EP1620070A2 (en)
CA (1) CA2524071A1 (en)
WO (1) WO2004096156A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008131074A1 (en) * 2007-04-19 2008-10-30 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Use of toll-like receptor-9 agonists, toll-like receptor-4 antagonists, and/or nuclear oligomerization domain-2 agonists for the treatment or prevention of toll-like receptor-4-associated disorders
US8518903B2 (en) 2007-04-19 2013-08-27 University of Pittsburgh—of the Commonwealth System of Higher Education Use of toll-like receptor-9 agonists
WO2009018431A2 (en) * 2007-08-01 2009-02-05 Idera Pharmaceuticals, Inc. Novel synthetic agonists of tlr9
US10668092B2 (en) 2010-09-24 2020-06-02 The John Hopkins University Compositions and methods for treatment of inflammatory disorders
US9072760B2 (en) 2010-09-24 2015-07-07 University of Pittsburgh—of the Commonwealth System of Higher Education TLR4 inhibitors for the treatment of human infectious and inflammatory disorders
WO2012088425A2 (en) 2010-12-22 2012-06-28 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Gap junction-enhancing agents for treatment of necrotizing enterocolitis and inflammatory bowel disease
US9562066B2 (en) 2012-09-25 2017-02-07 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Oral therapy of necrotizing enterocolitis
WO2024054992A1 (en) 2022-09-09 2024-03-14 Bristol-Myers Squibb Company Methods of separating chelator

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020192217A1 (en) * 2001-03-07 2002-12-19 Thierry Calandra Methods for regulation of immune responses to conditions involving mediator-induced pathology

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020192217A1 (en) * 2001-03-07 2002-12-19 Thierry Calandra Methods for regulation of immune responses to conditions involving mediator-induced pathology

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HEIT. A.: "Cutting Edge: Toll-Like Receptor 9 Expression is not Required for CpG DNA- Aided Cross-Presentation of DNA-Conjugated Antigens but Essential for Cross-Priming of CD8 T Cells.", J. IMMUNOL., vol. 170., no. 6, March 2003 (2003-03-01), pages 2802 - 5, XP008107810 *

Also Published As

Publication number Publication date
WO2004096156A2 (en) 2004-11-11
CA2524071A1 (en) 2004-11-11
EP1620070A2 (en) 2006-02-01

Similar Documents

Publication Publication Date Title
WO2004011611A3 (en) Taci antibodies and uses thereof
IL169165A0 (en) Polymeric reagents and methods for the preparation thereof
EP2949658A3 (en) Peptides that specifically bind HGF receptor (cMet) and uses thereof
EP3056511A3 (en) Il-1beta binding antibodies and fragments thereof
AU2002251913A1 (en) Hybrid antibodies and uses thereof
WO2005048957A3 (en) Novel insertion sites in pox vectors
WO2007060117A3 (en) Chimeric keratin-binding effector proteins
IL169804A (en) 254p1d6b proteins, nucleic acids encoding the same, processes for producing the same, antibodies binding thereto and uses thereof
WO2004037979A3 (en) Improved sso7-polymerase conjugate proteins
AU2002226211A1 (en) Individualized anti-cancer antibodies
WO2006054096A3 (en) Soluble bifunctional proteins
EP2316944A3 (en) Binding agents: chimeric ligand/receptor proteins
EP1617802A4 (en) Cngh0010 specific polynucleotides, polypeptides, antibodies, compositions, methods and uses.
WO2003038397A3 (en) Assay
AU2001244609A1 (en) Novel protein, dna thereof and process for producing the same
ZA200307365B (en) Antibodies specific for CD44V6.
GB0420062D0 (en) Assay methods,materials and preparations
AU2002359495A1 (en) Anti-tnf antibodies, compositions, methods and uses
WO2004096156A3 (en) Toll-like receptor 9 effector agents and uses thereof
WO2005065015A3 (en) Neutralizing antibodies and methods of use thereof
WO2007067189A3 (en) System and methods for biological assays
AU2003225976A1 (en) Anti-tnf antibodies, compositions, methods and uses
WO2001085779A3 (en) Protein complexes and assays for screening anti-cancer agents
AU2001248178A1 (en) Chlamydia transmembrane protein as antigen, corresponding dna fragments and uses thereof
AU2002365269A1 (en) Mut-il-18 or mut-il-18r proteins, antibodies, compositions, methods and uses

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2524071

Country of ref document: CA

Ref document number: 2006514267

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2004751272

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2004751272

Country of ref document: EP